MCID: NRG002
MIFTS: 53

Neurogenic Bladder

Categories: Nephrological diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Bladder

MalaCards integrated aliases for Neurogenic Bladder:

Name: Neurogenic Bladder 12 29 6 15
Neurogenic Dysfunction of the Urinary Bladder 12
Neurogenic Urinary Bladder Disorder 12
Urinary Bladder, Neurogenic 44
Neurogenic Urinary Bladder 73
Neuropathic Bladder 12
Bladder Neurogenic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:12143
ICD9CM 35 596.54
MeSH 44 D001750
NCIt 50 C79696
SNOMED-CT 68 23201000
UMLS 73 C0005697

Summaries for Neurogenic Bladder

MalaCards based summary : Neurogenic Bladder, also known as neurogenic dysfunction of the urinary bladder, is related to urofacial syndrome 1 and lethal congenital contracture syndrome 2, and has symptoms including seizures, vertigo and pain. An important gene associated with Neurogenic Bladder is EBF3 (EBF Transcription Factor 3), and among its related pathways/superpathways are Calcium signaling pathway and Arf6 trafficking events. The drugs Acetylcholine and Oxybutynin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, prostate and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Neurogenic bladder dysfunction, sometimes simply referred to as neurogenic bladder, is a dysfunction of... more...

Related Diseases for Neurogenic Bladder

Diseases related to Neurogenic Bladder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 urofacial syndrome 1 32.4 HPSE2 LRIG2
2 lethal congenital contracture syndrome 2 31.9 ERBB3 PIP5K1C
3 hinman syndrome 11.7
4 polyglucosan body neuropathy, adult form 11.3
5 adult polyglucosan body disease 11.3
6 lethal congenital contracture syndrome 3 11.1
7 peroxisome biogenesis disorder 10b 11.1
8 leukodystrophy, progressive, early childhood-onset 11.1
9 spinal cord injury 10.7
10 multiple sclerosis 10.5
11 myelomeningocele 10.5
12 acute cystitis 10.5
13 vesicoureteral reflux 1 10.4
14 neural tube defects 10.4
15 bacteriuria 10.4
16 bladder disease 10.3
17 herpes zoster 10.2
18 cystitis 10.2
19 bladder cancer 10.1
20 lethal congenital contracture syndrome 10.1 ERBB3 PIP5K1C
21 lethal congenital contracture syndrome 1 10.1 ERBB3 PIP5K1C
22 systemic lupus erythematosus 10.0
23 cerebral palsy 10.0
24 pyelonephritis 10.0
25 lupus erythematosus 10.0
26 low compliance bladder 10.0 CHRM2 P2RX2
27 anus, imperforate 10.0
28 prostatic hyperplasia, benign 9.9
29 anxiety 9.9
30 legionnaire disease 9.9
31 chronic kidney failure 9.9
32 diabetes mellitus 9.9
33 legionnaires' disease 9.9
34 legionellosis 9.9
35 tethered spinal cord syndrome 9.9
36 prostatic hypertrophy 9.9
37 neurogenic bowel 9.9
38 bladder neck obstruction 9.9
39 interstitial cystitis 9.9
40 pyuria 9.9
41 kidney disease 9.9
42 neuropathy 9.9
43 arachnoid cysts 9.9
44 depression 9.9
45 encephalopathy 9.9
46 achondroplasia 9.8
47 congenital anomalies of kidney and urinary tract 2 9.8
48 sacral defect with anterior meningocele 9.8
49 renal tubular acidosis 9.8
50 vitamin b12 deficiency 9.8

Comorbidity relations with Neurogenic Bladder via Phenotypic Disease Network (PDN): (show all 30)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Hypertension, Essential
Hypothyroidism Ischemic Heart Disease
Multiple Sclerosis Osteoporosis
Paralytic Ileus Paraplegia
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Prostatic Hypertrophy Protein-Energy Malnutrition
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia Urethral Stricture

Graphical network of the top 20 diseases related to Neurogenic Bladder:



Diseases related to Neurogenic Bladder

Symptoms & Phenotypes for Neurogenic Bladder

UMLS symptoms related to Neurogenic Bladder:


seizures, vertigo, pain, dysuria, meningism, reflex, abnormal, urgency of micturition, neurobehavioral manifestations, neuromuscular manifestations

MGI Mouse Phenotypes related to Neurogenic Bladder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 CHRM2 ERBB3 GBE1 P2RX1 P2RX2 PIP5K1C
2 homeostasis/metabolism MP:0005376 9.76 CHRM2 ERBB3 GBE1 HPSE2 P2RX2 PEX3
3 integument MP:0010771 9.43 CHRM2 ERBB3 LRIG2 PEX3 PIP5K1C TRPV1
4 nervous system MP:0003631 9.23 CHRM2 EBF3 ERBB3 GBE1 LRIG2 P2RX2

Drugs & Therapeutics for Neurogenic Bladder

Drugs for Neurogenic Bladder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
2
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Trimethoprim Approved, Vet_approved Phase 4,Phase 1,Phase 2 738-70-5 5578
5
Sulfamethoxazole Approved Phase 4,Phase 1,Phase 2 723-46-6 5329
6
Silodosin Approved Phase 4 160970-54-7
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Fosfomycin Approved Phase 4 23155-02-4 446987
9
Cefixime Approved, Investigational Phase 4 79350-37-1 5362065 54362
10 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
12 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2,Not Applicable
13 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 onabotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
18 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
19 Anesthetics Phase 4
20 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 2,Phase 3,Phase 1
21 Adrenergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
22 Adrenergic alpha-Antagonists Phase 4,Phase 2,Phase 3,Phase 1
23 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
24 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antitubercular Agents Phase 4,Phase 1,Phase 2
28 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
29 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
32 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Clavulanic Acids Phase 4
34 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Mandelic Acids Phase 4,Phase 3,Phase 2,Not Applicable
36 Solifenacin succinate Phase 4 242478-38-2
37
Tamsulosin Approved, Investigational Phase 2, Phase 3,Phase 1 106133-20-4 129211
38
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
39
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
40
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
41 Cranberry Approved, Investigational Phase 3
42
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
43
Ofloxacin Approved Phase 3 82419-36-1 4583
44
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
45
Fesoterodine Approved Phase 3 286930-03-8, 286930-02-7 6918558
46 Mirabegron Approved Phase 2, Phase 3,Early Phase 1 223673-61-8
47 tannic acid Approved Phase 2, Phase 3
48
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
49 Octenidine Investigational Phase 2, Phase 3 71251-02-0
50 Anti-Infective Agents, Local Phase 2, Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
2 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
3 Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder Completed NCT01228370 Phase 4 silodosin
4 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
5 Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
6 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
7 Quality of Life Intermittent Catheter Study Completed NCT01523743 Phase 4
8 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4 Oxybutynin transdermal system
9 Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome Completed NCT00277563 Phase 4
10 Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder Recruiting NCT01192568 Phase 4 Oxybutynin
11 Antiseptic-coated Intermittent Urinary Catheter Unknown status NCT02697162 Phase 2, Phase 3 Octenidine chloride
12 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
13 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
14 Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Completed NCT01716624 Phase 3 Oxybutynin;Botulinum Toxin A injection
15 Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder Completed NCT00796614 Phase 2, Phase 3 tamsulosin hydrochloride;Placebo
16 Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction Completed NCT00549939 Phase 3 Alfuzosin;Placebo
17 Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology Completed NCT00576823 Phase 3 Alfuzosin
18 Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Completed NCT00629720 Phase 3 alfuzosin (SL770499)
19 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
20 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
21 Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
22 Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients Completed NCT00280592 Phase 3 Cranberry;Placebo
23 A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections Completed NCT00258089 Phase 3 Levofloxacin
24 Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury Recruiting NCT03503513 Phase 2, Phase 3 Gentamicin Sulfate;Saline
25 A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Recruiting NCT01557244 Phase 3 Fesoterodine PR 4 mg;Fesoterodine PR 8 mg;Fesoterodine PR 8 mg;Oxybutynin;Fesoterodine PR;Fesoterodine BIC 2 mg;Fesoterodine BIC 4 mg
26 Vaginal Estriol in Multiple Sclerosis Not yet recruiting NCT03774407 Phase 2, Phase 3 vaginal estriol
27 Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients Terminated NCT02044510 Phase 2, Phase 3 Mirabegron;Placebo
28 Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) Unknown status NCT02591901 Phase 2 Uro vaxom
29 Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder Unknown status NCT02044965 Phase 1, Phase 2 Probiotic
30 Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization Unknown status NCT01305681 Phase 1, Phase 2
31 Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction Unknown status NCT00602186 Phase 1, Phase 2 tamsolusin;prazosin
32 PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder Completed NCT00340704 Phase 2 tamsulosin hydrochloride
33 Self Management in Urinary Catheter Users Completed NCT00883220 Phase 2
34 Multifaceted Treatment of Catheter-related Urinary Tract Infection Completed NCT00732238 Phase 2
35 Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation Completed NCT01243125 Phase 2 NVC-422, 0.2%;Sterile normal saline, 0.9%
36 Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury Not yet recruiting NCT03187795 Phase 2 Oxybutynin Chloride IR;Mirabegron
37 Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury Terminated NCT00512148 Phase 2
38 Augmentation Cystoplasty Using an Autologous Neo-Bladder Terminated NCT00419120 Phase 2
39 Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344) Terminated NCT00711087 Phase 2 BOTOX-A
40 NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder Terminated NCT00213577 Phase 2 type A botulinum toxin
41 Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Terminated NCT01598103 Phase 2 SAF312;Placebo to SAF312
42 Bacteriuria Eradication Through Probiotics Unknown status NCT00717600 Phase 1
43 Colonizing Neurogenic Bladders With Benign Flora Completed NCT00371631 Phase 1
44 Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution Completed NCT01429090 Phase 1 Vagantin®;methantheline solution
45 E. Coli for Prevention of Catheter UTI in SCI Patients Completed NCT00458471 Phase 1
46 Gene Expression in the Overactive Bladder in Children Unknown status NCT02086058
47 Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy Unknown status NCT02059798
48 Sterile Single-use vs Reused Polyvinylchloride Catheter For Intermittent Catheterization In Neurogenic Bladder Completed NCT03424499 Not Applicable
49 Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Completed NCT01299792
50 Can Dynamic Ultrasonography Replace Urodynamics in Follow-up of Patients With Myelomeningocele Completed NCT03550898 Not Applicable

Search NIH Clinical Center for Neurogenic Bladder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: urinary bladder, neurogenic

Genetic Tests for Neurogenic Bladder

Genetic tests related to Neurogenic Bladder:

# Genetic test Affiliating Genes
1 Neurogenic Bladder 29

Anatomical Context for Neurogenic Bladder

MalaCards organs/tissues related to Neurogenic Bladder:

41
Spinal Cord, Prostate, Testes, Brain, Kidney, Colon, Lymph Node

Publications for Neurogenic Bladder

Articles related to Neurogenic Bladder:

(show top 50) (show all 1011)
# Title Authors Year
1
Parkinsonian GM2 synthase knockout mice lacking mature gangliosides develop urinary dysfunction and neurogenic bladder. ( 30393144 )
2019
2
Surgical management of the neurogenic bladder after spinal cord injury. ( 29680953 )
2018
3
Intraspinal schwannoma and neurogenic bladder. ( 29543054 )
2018
4
The ability of prior urinary cultures results to predict future culture results in neurogenic bladder patients. ( 29799144 )
2018
5
Surgical Management of Anatomic Bladder Outlet Obstruction in Males with Neurogenic Bladder Dysfunction: A Systematic Review. ( 29551557 )
2018
6
Characterization and in vivo efficacy of a heptapeptide ODT formulation for the treatment of neurogenic bladder dysfunction. ( 29195918 )
2018
7
De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer. ( 29504654 )
2018
8
Anatomical Feasibility of Extradural Transferring S2 and S3 Ventral Roots to S1 Ventral Root for Restoring Neurogenic Bladder in Spinal Cord Injury. ( 29470276 )
2018
9
Re: Quality of Life after Suprapubic Catheter Placement in Patients with Neurogenic Bladder Conditions. ( 29310196 )
2018
10
Recommendations for urological follow-up of patients with neurogenic bladder secondary to spinal cord injury. ( 29569211 )
2018
11
Clinical outcomes of non-surgical management of detrusor leak point pressures above 40a88cm water in adults with congenital neurogenic bladder. ( 29488655 )
2018
12
Neurogenic bladder findings in patients with Congenital Zika Syndrome: A novel condition. ( 29494684 )
2018
13
Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson's disease and multiple system atrophy. ( 29356135 )
2018
14
Vesical fungus balls (fungal bezoars) by <i>Candida albicans</i> mimicking urothelial carcinoma in a patient with diabetic neurogenic bladder. ( 29556476 )
2018
15
Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. ( 29752515 )
2018
16
Analysis of bladder cancer subtypes in neurogenic bladder tumors. ( 29524970 )
2018
17
Current and future international patterns of care of neurogenic bladder after spinal cord injury. ( 29605828 )
2018
18
Evaluating a telehealth intervention for urinalysis monitoring in children with neurogenic bladder. ( 29804471 )
2018
19
Application of clean intermittent catheterization for neurogenic bladder in infants less than 1 year old. ( 29660959 )
2018
20
Posterior Reversible Encephalopathy Syndrome after Augmentation Cystoplasty in a Child with Neurogenic Bladder. ( 30050267 )
2018
21
The role of appetite-regulating hormones: Ghrelin and leptin in the nutritional status of children with neurogenic bladder due to myelomeningocele. ( 30488610 )
2018
22
A cross-sectional study of the catheter management of neurogenic bladder after traumatic spinal cord injury. ( 28580635 )
2018
23
Non-surgical urologic management of neurogenic bladder after spinal cord injury. ( 30051263 )
2018
24
TGF-β1 and connexin-43 expression in neurogenic bladder from rats with sacral spinal cord injury. ( 30070388 )
2018
25
Misplaced Foley catheter in ureter in a female with neurogenic bladder: a rare complication report. ( 30121570 )
2018
26
A Proof-of-Concept Study of Transcutaneous Magnetic Spinal Cord Stimulation for Neurogenic Bladder. ( 30135433 )
2018
27
A Review of Botulinum Toxin A for the Treatment of Neurogenic Bladder. ( 30138720 )
2018
28
Preventing urinary tract infections in patients with neurogenic bladder. ( 30153930 )
2018
29
Protocol for a randomized clinical trial investigating early sacral nerve stimulation as an adjunct to standard neurogenic bladder management following acute spinal cord injury. ( 30157824 )
2018
30
A Retrospective Case Series of High-Frequency Spinal Cord Stimulation (HF10-SCS) in Neurogenic Bladder Incontinence. ( 30169840 )
2018
31
Ancillary benefits of bladder chemodenervation for SCI neurogenic bladder. ( 30245851 )
2018
32
Safety, Feasibility, and Efficacy of Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury Neurogenic Bladder: A Randomized Control Pilot Trial. ( 30284350 )
2018
33
Management of neurogenic bladder in patients with Parkinson's disease: A systematic review. ( 30407660 )
2018
34
Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. ( 30511212 )
2018
35
Lower urinary tract symptoms treatment constraints assessment (LUTS-TCA): a new tool for a global evaluation of neurogenic bladder treatments. ( 30511213 )
2018
36
Applicability of botulinum toxin type A in paediatric neurogenic bladder management. ( 27748667 )
2017
37
Management of urinary tract infection with intravesical amikacin may increase the risk of bladder oxidative stress in children with neurogenic bladder. ( 28956280 )
2017
38
Application of data mining techniques to explore predictors of upper urinary tract damage in patients with neurogenic bladder. ( 28832768 )
2017
39
Re: Barriers to Transition in Young Adults with Neurogenic Bladder. ( 29144923 )
2017
40
The management of paediatric neurogenic bladder: an approach in a resource-poor setting. ( 28714784 )
2017
41
Afferent Pathway-Mediated Effect of I+1 Adrenergic Antagonist, Tamsulosin, on the Neurogenic Bladder After Spinal Cord Injury. ( 28954467 )
2017
42
What do we know about neurogenic bladder prevalence and management in developing countries and emerging regions of the world? ( 28623162 )
2017
43
Real world treatment patterns in the neurogenic bladder population: a systematic literature review. ( 29354507 )
2017
44
Diagnostic value of ultrasonography in spinal abnormalities among children with neurogenic bladder. ( 28848632 )
2017
45
Follow-up urodynamics in patients with neurogenic bladder. ( 29021649 )
2017
46
The Neurogenic Bladder Symptom Score (NBSS): a secondary assessment of its validity, reliability among people with a spinal cord injury. ( 29184133 )
2017
47
Pharmacotherapy for Pediatric Neurogenic Bladder. ( 28712052 )
2017
48
Identifying Patients with High-Risk Neurogenic Bladder: Beyond Detrusor Leak Point Pressure. ( 28716324 )
2017
49
Role of gentamicin in reducing urinary tract infections in patients with neurogenic bladder. ( 29257743 )
2017
50
Correlating spinal cord injuries with neurogenic bladder pathophysiology. ( 28090756 )
2017

Variations for Neurogenic Bladder

ClinVar genetic disease variations for Neurogenic Bladder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 EBF3 NM_001005463.2(EBF3): c.512G> A (p.Gly171Asp) single nucleotide variant Pathogenic rs1057519437 GRCh37 Chromosome 10, 131755564: 131755564
2 EBF3 NM_001005463.2(EBF3): c.512G> A (p.Gly171Asp) single nucleotide variant Pathogenic rs1057519437 GRCh38 Chromosome 10, 129957300: 129957300

Expression for Neurogenic Bladder

Search GEO for disease gene expression data for Neurogenic Bladder.

Pathways for Neurogenic Bladder

Pathways related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.2 CHRM2 ERBB3 P2RX1 P2RX2
2 10.6 CHRM2 PIP5K1C

GO Terms for Neurogenic Bladder

Cellular components related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.72 CHRM2 ERBB3 P2RX1 P2RX2 TRPV1
2 postsynaptic membrane GO:0045211 9.33 CHRM2 P2RX1 TRPV1
3 integral component of postsynaptic membrane GO:0099055 9.26 CHRM2 P2RX1
4 neuronal cell body GO:0043025 9.26 CHRM2 LRIG2 P2RX2 TRPV1
5 integral component of nuclear inner membrane GO:0005639 8.62 P2RX1 P2RX2

Biological processes related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.63 P2RX1 P2RX2 TRPV1
2 regulation of synaptic vesicle exocytosis GO:2000300 9.43 CHRM2 P2RX1
3 cation transmembrane transport GO:0098655 9.4 P2RX1 P2RX2
4 regulation of smooth muscle contraction GO:0006940 9.37 CHRM2 P2RX1
5 response to ATP GO:0033198 9.32 P2RX1 P2RX2
6 behavioral response to pain GO:0048266 9.26 P2RX2 TRPV1
7 purinergic nucleotide receptor signaling pathway GO:0035590 9.16 P2RX1 P2RX2
8 excitatory postsynaptic potential GO:0060079 9.13 P2RX1 P2RX2 TRPV1
9 urinary bladder smooth muscle contraction GO:0014832 8.62 P2RX2 TRPV1

Molecular functions related to Neurogenic Bladder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.43 P2RX1 P2RX2 TRPV1
2 ligand-gated ion channel activity GO:0015276 9.37 P2RX2 TRPV1
3 cation channel activity GO:0005261 9.32 P2RX1 TRPV1
4 extracellularly ATP-gated cation channel activity GO:0004931 9.16 P2RX1 P2RX2
5 ATP-gated ion channel activity GO:0035381 8.96 P2RX1 P2RX2
6 purinergic nucleotide receptor activity GO:0001614 8.62 P2RX1 P2RX2

Sources for Neurogenic Bladder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....